VEMLIDY is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults and pediatric patients 6 years of age and older and weighing at least 25 kg with compensated liver disease.
From the U.S. FDA-approved label for Tenofovir alafenamide. Full label: DailyMed.
VEMLIDY is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults and pediatric patients 6 years of age and older and weighing at least 25 kg with compensated liver disease.
From the U.S. FDA-approved label for Tenofovir alafenamide. Full label: DailyMed.
Testing: Prior to initiation of VEMLIDY, test patients for HIV infection. Prior to or when initiating VEMLIDY, and during treatment on a clinically appropriate schedule, assess serum creatinine, estimated creatinine clearance, urine glucose, and urine protein in all patients. Also assess serum phosphorus in patients with chronic kidney disease.
Directions from the U.S. FDA-approved label — your doctor or pharmacist may advise differently.
HBV and HIV-1 coinfection: VEMLIDY alone is not recommended for the treatment of HIV-1 infection. HIV-1 resistance may develop in these patients. New onset or worsening renal impairment: Prior to or when initiating VEMLIDY, and during treatment on a clinically appropriate schedule, assess serum creatinine, estimated creatinine clearance, urine glucose, and urine protein in all patients. Also assess serum phosphorus in patients with chronic kidney disease.
Warnings and precautions excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor before use.
The following adverse reactions are discussed in other sections of the labeling: Severe Acute Exacerbation of Hepatitis B New Onset or Worsening of Renal Impairment Lactic Acidosis/Severe Hepatomegaly with Steatosis Most common adverse reaction (incidence greater than or equal to 10%, all grades) is headache. To report SUSPECTED ADVERSE REACTIONS, contact Gilead Sciences, Inc.
Excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor about side effects.
9 products from 9 makers in the NepalDoc medicine catalog use this generic:
| Brand | Composition | Maker | Pack |
|---|---|---|---|
| Durataf 25mg Tablet | Tenofovir Alafenamide (25mg) | Dr Reddy's Laboratories Ltd | bottle of 30 tablets |
| Emtaf-B Tablet | Tenofovir Alafenamide (25mg) | Emcure Pharmaceuticals Ltd | bottle of 30 tablets |
| Hepbest Tablet | Tenofovir Alafenamide (25mg) | Mylan Pharmaceuticals Pvt Ltd | bottle of 30 tablets |
| Tafero Tablet | Tenofovir Alafenamide (25mg) | Hetero Healthcare Limited | bottle of 30 tablets |
| Tafnat Tablet | Tenofovir Alafenamide (25mg) | Natco Pharma Ltd | bottle of 30 tablets |
| Tafsure Tablet | Tenofovir Alafenamide (25mg) | Aprazer Healthcare Pvt Ltd | bottle of 30 tablets |
| Tenohep AF Tablet | Tenofovir Alafenamide (25mg) | Zydus Cadila | bottle of 30 tablets |
| Tentide AF 25mg Tablet | Tenofovir Alafenamide (25mg) | Sun Pharmaceutical Industries Ltd | bottle of 30 tablets |
| Tenvir-AF Tablet | Tenofovir Alafenamide (25mg) | Cipla Ltd | bottle of 30 tablets |
Brand list from the NepalDoc medicine catalog. Availability varies by pharmacy — call ahead to confirm stock.
Store below 30 °C (86 °F). Keep container tightly closed. Dispense only in original container.
Storage information from the U.S. FDA-approved label.
This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. NLEM listing does not guarantee that a medicine is in stock at any pharmacy.
